Search details
1.
Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling.
Bioorg Chem
; 143: 107016, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38086239
2.
Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer.
Bioorg Chem
; 142: 106952, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37952486
3.
Discovery of novel pyrrolo [2,3-d] pyrimidine derivatives as potent FAK inhibitors based on cyclization strategy.
Bioorg Chem
; 139: 106713, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37459823
4.
Discovery of potent and selective HPK1 inhibitors based on the 2,4-disubstituted pyrimidine scaffold with immune modulatory properties for ameliorating T cell exhaustion.
Bioorg Chem
; 139: 106728, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37536217
5.
The copper-catalyzed oxidation of arylmethyl triazines with H2O toward the oxidant-free synthesis of aroyl triazines.
Org Biomol Chem
; 20(27): 5406-5411, 2022 07 13.
Article
in English
| MEDLINE | ID: mdl-35521790
6.
HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.
Bioorg Chem
; 105: 104377, 2020 12.
Article
in English
| MEDLINE | ID: mdl-33091668
7.
Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
J Enzyme Inhib Med Chem
; 35(1): 1606-1615, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-32779949
8.
Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping.
J Enzyme Inhib Med Chem
; 34(1): 808-817, 2019 Dec.
Article
in English
| MEDLINE | ID: mdl-30879350
9.
Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody.
Eur J Med Chem
; 267: 116206, 2024 Mar 05.
Article
in English
| MEDLINE | ID: mdl-38350360
10.
Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML.
Biomed Pharmacother
; 173: 116315, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38394852
11.
The progress of molecules and strategies for the treatment of HBV infection.
Front Cell Infect Microbiol
; 13: 1128807, 2023.
Article
in English
| MEDLINE | ID: mdl-37009498
12.
Current advances and development strategies of orally bioavailable PROTACs.
Eur J Med Chem
; 261: 115793, 2023 Dec 05.
Article
in English
| MEDLINE | ID: mdl-37708797
13.
The Activity of Novel BCR-ABL Small-Molecule Degraders Containing Pyrimidine Rings and Their Role in Overcoming Drug Resistance.
J Oncol
; 2022: 4056398, 2022.
Article
in English
| MEDLINE | ID: mdl-36349200
14.
The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
Eur J Med Chem
; 238: 114442, 2022 Aug 05.
Article
in English
| MEDLINE | ID: mdl-35551036
15.
The synthesis of anticancer sulfonated indolo[2,1-a]isoquinoline and benzimidazo[2,1-a]isoquinolin-6(5H)-ones derivatives via a free radical cascade pathway.
RSC Adv
; 12(16): 9763-9772, 2022 Mar 25.
Article
in English
| MEDLINE | ID: mdl-35424925
16.
Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
J Med Chem
; 65(13): 9096-9125, 2022 07 14.
Article
in English
| MEDLINE | ID: mdl-35671249
17.
Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer's disease.
ACS Omega
; 7(30): 26308-26315, 2022 Aug 02.
Article
in English
| MEDLINE | ID: mdl-35936449
18.
Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery.
Front Chem
; 9: 639176, 2021.
Article
in English
| MEDLINE | ID: mdl-33777902
19.
Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression.
Leuk Res
; 109: 106649, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34271301
20.
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
Eur J Med Chem
; 210: 112981, 2021 Jan 15.
Article
in English
| MEDLINE | ID: mdl-33160761